Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis.
1 We have assessed the thromboxane synthetase inhibitor, dazoxiben (UK 37248), during dialysis in a double-blind, placebo-controlled crossover study. 2 Thromboxane generation was markedly inhibited, and there was an increase in serum 6-keto prostaglandin F1 alpha levels during active treatment studies. 3 We were unable to demonstrate any reduction of platelet activation, or dialyser fibrin deposition, nor were heparin requirements altered by the drug. 4 Dazoxiben had no adverse effects.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D010976:Platelet Count; D006435:Renal Dialysis; D013929:Thromboxane B2 / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D007093:Imidazoles; C029166:dazoxiben; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D010088:Oxidoreductases; D013930:Thromboxane-A Synthase